Market Closed -
Nasdaq
04:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
4
USD
|
+0.25%
|
|
+20.48%
|
+89.57%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
271.7
|
493.7
|
392.8
|
922.6
|
1,146
|
2,373
|
-
|
-
|
Enterprise Value (EV)
1 |
271.7
|
493.7
|
392.8
|
922.6
|
1,162
|
2,287
|
2,308
|
2,104
|
P/E ratio
|
-3.78
x
|
-5.68
x
|
-3.49
x
|
-6.54
x
|
-6.59
x
|
-11.4
x
|
-21.8
x
|
62.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
591
x
|
1,951
x
|
282
x
|
1,548
x
|
4,835
x
|
41.9
x
|
9.84
x
|
4.92
x
|
EV / Revenue
|
591
x
|
1,951
x
|
282
x
|
1,548
x
|
4,902
x
|
40.4
x
|
9.58
x
|
4.37
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-6
x
|
-10.6
x
|
-42.9
x
|
13.4
x
|
EV / FCF
|
-6.14
x
|
-2.87
x
|
-3.38
x
|
-
|
-
|
-10.5
x
|
-20.4
x
|
35.1
x
|
FCF Yield
|
-16.3%
|
-34.8%
|
-29.6%
|
-
|
-
|
-9.49%
|
-4.9%
|
2.85%
|
Price to Book
|
2.01
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
199,778
|
310,472
|
321,949
|
381,235
|
543,064
|
593,133
|
-
|
-
|
Reference price
2 |
1.360
|
1.590
|
1.220
|
2.420
|
2.110
|
4.000
|
4.000
|
4.000
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/16/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.46
|
0.253
|
1.393
|
0.596
|
0.237
|
56.59
|
241
|
481.9
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-193.5
|
-215.1
|
-53.87
|
156.7
|
EBIT
1 |
-72.5
|
-76.91
|
-114
|
-138.6
|
-193.9
|
-219.4
|
-100.6
|
90.42
|
Operating Margin
|
-15,761.96%
|
-30,400.4%
|
-8,183.7%
|
-23,246.64%
|
-81,832.91%
|
-387.65%
|
-41.72%
|
18.76%
|
Earnings before Tax (EBT)
1 |
-68.55
|
-75.62
|
-116.1
|
-141.9
|
-184.1
|
-217.8
|
-90
|
76.81
|
Net income
1 |
-68.55
|
-75.62
|
-116.1
|
-141.9
|
-184.1
|
-218
|
-108.8
|
75.25
|
Net margin
|
-14,901.74%
|
-29,888.14%
|
-8,335.39%
|
-23,808.89%
|
-77,690.72%
|
-385.22%
|
-45.12%
|
15.62%
|
EPS
2 |
-0.3600
|
-0.2800
|
-0.3500
|
-0.3700
|
-0.3200
|
-0.3517
|
-0.1833
|
0.0640
|
Free Cash Flow
1 |
-44.24
|
-172
|
-116.1
|
-
|
-
|
-217
|
-113
|
60
|
FCF margin
|
-9,617.83%
|
-67,973.12%
|
-8,334.82%
|
-
|
-
|
-383.44%
|
-46.88%
|
12.45%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
38.29%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
79.73%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/16/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.04
|
0.123
|
0.073
|
0.297
|
0.103
|
0.021
|
0.029
|
0.164
|
0.023
|
0.304
|
0.0649
|
19.5
|
36.77
|
49.48
|
56.38
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-30.98
|
-28.68
|
-27.98
|
-39.95
|
-41.95
|
-40.09
|
-51.95
|
-47.61
|
-54.29
|
-56.13
|
-67.31
|
-53.58
|
-42.35
|
-32.67
|
-39.1
|
Operating Margin
|
-2,979.04%
|
-23,313.01%
|
-38,323.29%
|
-13,450.51%
|
-40,729.13%
|
-190,914.29%
|
-179,141.38%
|
-29,031.71%
|
-236,039.13%
|
-18,465.13%
|
-103,774.79%
|
-274.75%
|
-115.19%
|
-66.03%
|
-69.35%
|
Earnings before Tax (EBT)
1 |
-32.02
|
-30.1
|
-28.12
|
-41.05
|
-42.64
|
-38.12
|
-49.23
|
-44.8
|
-51.97
|
-55.39
|
-66.3
|
-53.36
|
-42.55
|
-34.8
|
-30.3
|
Net income
1 |
-32.02
|
-30.1
|
-28.12
|
-41.05
|
-42.64
|
-38.12
|
-49.23
|
-44.8
|
-51.97
|
-55.39
|
-65.84
|
-53.22
|
-43.41
|
-40.03
|
-38.1
|
Net margin
|
-3,078.56%
|
-24,469.92%
|
-38,516.44%
|
-13,821.89%
|
-41,393.2%
|
-181,533.33%
|
-169,748.28%
|
-27,320.12%
|
-225,973.91%
|
-18,220.39%
|
-101,517.11%
|
-272.88%
|
-118.06%
|
-80.89%
|
-67.57%
|
EPS
2 |
-0.1000
|
-0.0900
|
-0.0700
|
-0.1000
|
-0.1000
|
-0.0700
|
-0.0900
|
-0.0800
|
-0.0900
|
-0.0900
|
-0.1033
|
-0.0900
|
-0.0683
|
-0.0567
|
-0.0533
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/9/22
|
8/11/22
|
11/3/22
|
3/16/23
|
5/11/23
|
8/3/23
|
11/2/23
|
2/28/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
15.9
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
85.5
|
64.1
|
269
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.082
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-44.2
|
-172
|
-116
|
-
|
-
|
-217
|
-113
|
60
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.6800
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.41
|
0.4
|
0.21
|
-
|
-
|
5
|
7
|
9
|
Capex / Sales
|
89.78%
|
158.5%
|
14.86%
|
-
|
-
|
8.83%
|
2.9%
|
1.87%
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/16/23
|
2/28/24
|
-
|
-
|
-
|
Average target price
6.071
USD Spread / Average Target +51.79% Consensus |
1st Jan change
|
Capi.
|
---|
| +89.57% | 2.37B | | +18.72% | 123B | | +14.53% | 107B | | -2.88% | 24.01B | | +2.18% | 22.59B | | -10.09% | 18.16B | | -41.04% | 16.84B | | -11.83% | 16.23B | | +1.46% | 13.43B | | +24.22% | 11.32B |
Bio Therapeutic Drugs
|